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Background
Maraviroc is a new drug used to treat HIV infection from
the new class of drugs called CCR5 entry inhibitors. As the
active principle of these drugs is to block the CCR5-recep-
tor on the surface of the target cells, it has to be known if
the virus in the patient is using only CCR5 as co-receptor
or if there are populations that can also use CXCR4. There-
fore, an assay to determine the tropism has to be per-
formed before starting a therapy. Besides phenotypic
assays like the TROFILE® assay by Monogram, used in the
approval studies, there exist several genotyping systems
like geno2pheno-coreceptor, Wetcat (providing five dif-
ferent genotypic tropism schemes) and WebPSSM.
Methods
We compared the results of 310 patient samples using the
geno2pheno-coreceptor with the results of the TROFILE
assay.
Summary of results
The agreement between the TROFILE assay and
geno2pheno[co-receptor] (using a false positive rate of
20%) was 75%, compared to 84% for WebPSSM.
Although the performance of geno2pheno-coreceptor
seems not superior compared to the other genotypic sys-
tems, this approach only classifies 23% of the 104
CXCR4-tropic samples false as CCR5-tropic, whereas
WebPSSM and Wetcat have a higher amount of false
CCR5-tropic classification. See Figure 1.
Although geno2pheno has the unique ability to add addi-
tional laboratory parameters into the analysis, the use of
these data has no beneficial effect on the prediction. For
65 of the proviral samples, additional TROFILE results
and results from viral RNA sequencing were available.
Concordance between viral and proviral results was 74%,
with a slightly higher rate of X4 detection (42% vs. 37%).
Conclusion
The results of the genotypic classification approaches
show similar results as comparison of phenotypic
approaches. Due to our experiences, a differentiated
approach using the geno2pheno system provides the best
results in CXCR4 usage prediction. For patients with
severely limited therapeutic options we suggest the use of
CCR5 blockers only if the geno2pheno system, using a
FPR of 5%, does not predict CXCR4 usage. The other side
of the patient spectrum with many antiretroviral therapy
options requires a more stringent setting with a FPR of
20%. For this highly personalized approach, close co-
operation between the clinicians and virologists is essen-
tial. Sequencing of proviral DNA is leading to similar
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results as sequencing viral plasma RNA, with a slightly
higher rate of X4 detection, thus offering an possibility for
tropism testing at a plasma viral load below detection
limit.
Agreement between genotypic methods and TROFILE® N = 310 Figure 1
Agreement between genotypic methods and TROFILE® N = 310.